Concepedia
Statistics
Publications
3
Citations
79
H-Index
Active since
2017
Affiliations
Renji Hospital(Current)
Ruijin Hospital
Shanghai Jiao Tong University
Zhongshan Hospital
Zhongshan Hospital of Xiamen University
Dengqiang Lin is an author at Renji Hospital specializing in medicine, oncology, and pi3k-akt signaling pathway.
Publications per year
2017–2022
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Yunze Xu, Wen Kong, Ming Cao et al. · European Urology · 2022 · 55 citations
Medicine, Cancer Biology, Oncology +17
HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.
Feifei Xu, Dengqiang Lin, Wen Jiang et al. · PubMed · 2019 · 13 citations
Medicine, Oncology, Pharmacology +17
NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
Dengqiang Lin, Xing Xie, Yunze Xu et al. · OncoTargets and Therapy · 2017 · 11 citations · Full text
Medicine, Oncology, Pharmacology +16
1–3 of 3